LLY240628P650000
- 0.07
- 0.000.00%
Eli Lilly and Co Newsroom
"Weight-loss miracle drug" has new benefits. Research shows that GLP-1 drugs may help reduce the risk of cancer.
The Centers for Disease Control and Prevention (CDC) in the USA states that obesity increases the risk of developing 13 cancers, while the latest research examines the health records of diabetes patients and finds that some diabetes treatments may help prevent obesity-related cancers.
Small, Mid-size Biotechs Could See M&A Action in H2 - PwC
The Trader: Conagra Took a GLP-1 Hit. Why Its Stock Is Worth a Look. -- Barron's
By Paul R. La Monica Ozempic and other popular injectable GLP-1 drugs aren't just helping dieters shed pounds. They're also leading to share price losses for top food stocks. Take a look at Conagra B
Study Links GLP-1 Drugs, Metformin to Lower Risk of Certain Cancers
What's Going On With Eli Lilly Shares Friday?
Eli Lilly and Co. (NYSE:LLY) shares are experiencing increased activity Friday afternoon. Here's what you need to know.What's Happening: Morgan Stanley has maintained its Overweight rating on Eli Lill
Shares of Lilly and Novo Nordisk Are Trading Higher Following a Study Showing Patients Taking GLP-1 Treatments Have a Reduced Risk of Developing Obesity-related Cancers.
Shares of Lilly and Novo Nordisk Are Trading Higher Following a Study Showing Patients Taking GLP-1 Treatments Have a Reduced Risk of Developing Obesity-related Cancers.
GLP-1 Treatments Such As Wegvoy, Mounjaro Cut Obesity-Related Cancer Risks, Study Finds
In a study published in JAMA Network, patients with type 2 diabetes taking GLP-1 treatments have a reduced risk of developing ten types of obesity-related cancers compared to those on insulin and othe
'Ozempic May Lower Risk of Obesity-Related Cancers, Study Finds' - Bloomberg Law
'Ozempic May Lower Risk of Obesity-Related Cancers, Study Finds' - Bloomberg Law
Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
Eli Lilly Remains an Equities Outlier
Smart Money Is Betting Big In LLY Options
High-rolling investors have positioned themselves bearish on Eli Lilly and Co (NYSE:LLY), and it's important for retail traders to take note.\This activity came to our attention today through Benzinga
Morgan Stanley Maintains Overweight on Eli Lilly and Co, Maintains $1023 Price Target
Morgan Stanley analyst Terence Flynn maintains Eli Lilly and Co (NYSE:LLY) with a Overweight and maintains $1023 price target.
Eli Lilly and Co Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/05/2024 14.02% Morgan Stanley $1023 → $1023 Maintains Overweight 07/03/2024 11.57% BMO Capital $1001 →
Here's How Much $100 Invested In Eli Lilly and Co 15 Years Ago Would Be Worth Today
Eli Lilly and Co (NYSE:LLY) has outperformed the market over the past 15 years by 11.54% on an annualized basis producing an average annual return of 24.56%. Currently, Eli Lilly and Co has a market c
Today's Analyst Rating | Microsoft Price Target Raised to $480 by Raymond James, Itau Unibanco Upgrades Apple to Hold
Jul 4, Wall Street analysts have updated their stock ratings today including $Microsoft(MSFT.US)$ and $Apple(AAPL.US)$.
Technology stocks are the biggest winners in the first half of the year, how does the US stock market view the future?
In the first half of 2024, the US stock market continued to rise, with the Dow Jones Industrial Average up 3.93% and the S&P 500 index far exceeding historical average gains. The Nasdaq index has repeatedly hit new highs and is still leading the US stock market.
Nvidia brings abundant profits! Who are the winners? And who missed the opportunity?
The fund holdings of Nvidia and its position ratios largely determine the winners and losers of this quarter.
Crossing the Alzheimer's disease R&D death valley: Eli Lilly and Co and WeiChai Pharmaceuticals have been approved for two drugs, while HengRui Pharmaceuticals is in the early stage of research and development.
Due to high research and development barriers, there are fewer participants in the Chinese AD new drug research and development market.
A Harvard study shows that semaglutide is related to rare vision loss. Novo Nordisk (NVO.US) leads the weight loss drug concept stocks in decline.
A Harvard study shows that the weight loss drugs Ozempic and Wegovy from Novo Nordisk A/S may be associated with rare vision loss.
These Funds Made Heady Gains. Thank Nvidia.
Which fund held Nvidia—and how big their stake was—went a long way to determining winners and losers in the quarter. Here's who benefited, and who missed the boat.